Polycarboxylic Acid Or Salt Thereof Patents (Class 514/574)
  • Patent number: 11786495
    Abstract: This invention describes the potential benefits of chronic oral administration of triethyl citrate (TEC) for the treatment of Alzheimer's disease and atherosclerosis. Evidence is presented that TEC crosses the blood brain barrier via passive diffusion, and the pharmacologic properties of TEC are distinct from administration of citrate salts. Further clinical trials in animal and human subjects is encouraged.
    Type: Grant
    Filed: November 15, 2021
    Date of Patent: October 17, 2023
    Inventor: Joel Steven Goldberg
  • Patent number: 11760714
    Abstract: The invention provides methods of preparing 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid and methods of making a pharmaceutical material comprising a purified amount of 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid. Also provided are compositions and pharmaceutical materials including a purified amount of 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid as well as methods of treating various diseases and conditions using the compositions and pharmaceutical materials.
    Type: Grant
    Filed: January 18, 2022
    Date of Patent: September 19, 2023
    Assignee: Esperion Therapeutics, Inc.
    Inventors: Richard Copp, Mohamed Abdelnasser, Christopher M. Cimarusti, Jonathan Lane, Michael Barkman, Rasidul Amin, Arthur John Cooper, Damodaragounder Gopal, Philipp Selig
  • Patent number: 11744814
    Abstract: Provided is a method of treating a subject, including: (i) determining an initial level of blood oxygen saturation in the subject, and (ii) administering to the subject a therapeutically effective amount of a formulation including HCA, wherein HCA is (?)-hydroxycitric acid, a salt thereof, or a derivative thereof, thereby increasing blood oxygen saturation. Provided is a kit including HCA and instructions directing a subject to ingest the HCA if the subject is determined to have unhealthily low blood oxygen saturation. Provided is a method of treating a subject, including: (i) determining an initial level of blood hemoglobin in the subject, and (ii) administering to the subject a therapeutically effective amount of a formulation including HCA, thereby increasing blood hemoglobin.
    Type: Grant
    Filed: May 25, 2021
    Date of Patent: September 5, 2023
    Assignee: GLYKON TECHNOLOGIES GROUP, LLC
    Inventor: Daniel E. Clouatre
  • Patent number: 11642325
    Abstract: Various embodiments of this invention are directed to pharmaceutical compositions and methods for treating disease. The compositions of such embodiments include dicarboxylic acid compounds containing electron withdrawing groups, alkyl esters of dicarboxylic acids containing electron withdrawing groups, or compounds of Formulae I to X. The methods of various embodiments include administering an effective amount of any of these pharmaceutical compositions to a patient in need of treatment.
    Type: Grant
    Filed: July 27, 2020
    Date of Patent: May 9, 2023
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Bruce A. Freeman, Francisco J. Schopfer
  • Patent number: 11613511
    Abstract: The invention provides methods of preparing 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid and methods of making a pharmaceutical material comprising a purified amount of 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid. Also provided are compositions and pharmaceutical materials including a purified amount of 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid as well as methods of treating various diseases and conditions using the compositions and pharmaceutical materials.
    Type: Grant
    Filed: May 12, 2022
    Date of Patent: March 28, 2023
    Assignee: Esperion Therapeutics, Inc.
    Inventors: Richard Copp, Mohamed Abdelnasser, Christopher M. Cimarusti, Jonathan Lane, Michael Barkman, Rasidul Amin, Arthur John Cooper, Damodaragounder Gopal, Philipp Selig
  • Patent number: 11517533
    Abstract: Described herein is a method for forming multi-layer drug dosage forms having at least two layers. In the method, a first formulation comprising a non-gelling matrix forming agent and having a first density is dosed into a preformed mold. A second formulation comprising a non-gelling matrix former and having a second density not equal to the first density is subsequently dosed into the preformed mold. Then, the combination of the formulations dosed into the mold is freeze dried to form the multi-layer dosage form having at least two layers. The use of a density difference between the first and second formulations ensures formation of a product with two distinct layers.
    Type: Grant
    Filed: October 25, 2017
    Date of Patent: December 6, 2022
    Assignee: Catalent U.K. Swindon Zydis Limited
    Inventors: Leon Paul Grother, Keiko Tsutsumi, Rosaleen Theresa McLaughlin, Yik Teng Wong
  • Patent number: 11458091
    Abstract: Drug products adapted for nasal delivery, comprising a pre-primed device filled with a pharmaceutical composition comprising nalmefene are provided. Methods of treating opioid overdose with the drug products are also provided.
    Type: Grant
    Filed: November 9, 2017
    Date of Patent: October 4, 2022
    Assignees: Opiant Pharmaceuticals, Inc., Aegis Therapeutics, LLC
    Inventors: Roger Crystal, Edward T. Maggio
  • Patent number: 11446223
    Abstract: The present invention relates to an anti-aging composition. More specifically, the anti-aging composition according to the present invention is highly stable, harmless to the body, and effective in reducing wrinkles and improving elasticity of the skin due to the superb capability for stimulating collagen biosynthesis.
    Type: Grant
    Filed: April 7, 2017
    Date of Patent: September 20, 2022
    Assignee: NEOPHARM CO., LTD.
    Inventors: Se Kyoo Jeong, Bu-Mahn Park, Kyung Sook Yoo, Sung Woo Kim, Hye Seong Shin
  • Patent number: 11298329
    Abstract: The present invention is directed to antiviral compositions that provide efficacy against non-envelope viruses such as noroviruses. The antiviral compositions comprise an alkyl 2-hydroxycarboxylic acid and an effective amount of a sulfonated surfactant. The composition may be used as a topical on human skin, as a hand sanitizer or as a hard surface cleaning composition.
    Type: Grant
    Filed: July 2, 2020
    Date of Patent: April 12, 2022
    Assignee: ECOLAB USA INC.
    Inventors: Daniel E. Pedersen, Hilina Emiru, Carter Martin Silvernail
  • Patent number: 11278507
    Abstract: Methods for stimulating the G protein receptor (Gpr91) pathway in intestinal cells to release IL-25 and enhance a type II immune response in the subject are useful in the treatment or prevention of bacterial or parasitic infection. Similarly methods and compositions used therein to inhibit or stimulate GPR91 are useful for the treatment or inhibition of certain diseases, such as irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), and Crohn's disease.
    Type: Grant
    Filed: August 21, 2017
    Date of Patent: March 22, 2022
    Assignee: Monell Chemical Senses Center
    Inventors: Peihua Jiang, Weiwei Lei
  • Patent number: 11213535
    Abstract: The present invention is related to a composition comprising phytic acid or a phytate salt, magnesium in the form of salt, hydroxide or oxide and optionally at least one polyphenol. These components may be in isolated form or be part of an enriched plant extract. The invention is also related to the use of this composition for the treatment of renal lithiasis, preferably calcium or calcium oxalate lithiasis, either in the form of a medicament, a nutraceutical or functional food or food supplement.
    Type: Grant
    Filed: April 14, 2015
    Date of Patent: January 4, 2022
    Assignee: UNIVERSITAT DE LES ILLES BALEARS
    Inventors: Félix Grases Freixedas, Antonia Costa Bauzá, Rafael María Prieto Almirall, Adrián Rodríguez Rodríguez
  • Patent number: 10751310
    Abstract: Various embodiments of this invention are directed to pharmaceutical compositions and methods for treating disease. The compositions of such embodiments include dicarboxylic acid compounds containing electron withdrawing groups, alkyl esters of dicarboxylic acids containing electron withdrawing groups, or compounds of Formulae I to X. The methods of various embodiments include administering an effective amount of any of these pharmaceutical compositions to a patient in need of treatment.
    Type: Grant
    Filed: March 2, 2017
    Date of Patent: August 25, 2020
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Bruce A. Freeman, Francisco J. Schopfer
  • Patent number: 10744234
    Abstract: Provided is a method for preventing postoperative adhesion of an organ in a wound site using the application of an antiadhesive material thereto. The antiadhesive material contains a poly-?-glutamic acid having a weight-average molecular weight of 600,000 to 13,000,000, or a kinematic viscosity at 37° C. of 2 cSt to 15 cSt when dissolved in distilled water at a concentration of 0.05% by mass and/or a salt thereof, as an effective ingredient. The antiadhesive material may be in a form such as powder, and therefore, for example, is easy to handle even in relatively localized surgery such as endoscopic surgery and can more reliably prevent adhesion.
    Type: Grant
    Filed: September 26, 2017
    Date of Patent: August 18, 2020
    Assignee: NIPRO CORPORATION
    Inventors: Yusuke Nakamura, Kazuhisa Matsuda
  • Patent number: 10695275
    Abstract: The present invention relates to an anti-aging composition. More specifically, the anti-aging composition according to the present invention is highly stable, harmless to the body, and effective in reducing wrinkles and improving elasticity of the skin due to the superb capability for stimulating collagen biosynthesis.
    Type: Grant
    Filed: April 7, 2017
    Date of Patent: June 30, 2020
    Assignee: NEOPHARM CO., LTD.
    Inventors: Se Kyoo Jeong, Bu-Mahn Park, Kyung Sook Yoo, Sung Woo Kim, Hye Seong Shin
  • Patent number: 10654882
    Abstract: The present invention provides a nicotinamide mononucleotide derivative, or salt thereof, which is a compound represented by general formula (1), wherein R1 and R2 respectively and independently represent a hydrogen atom or acyl group having 3 to 30 carbon atoms, the hydrocarbon group bound to the carbonyl carbon of the acyl group is a linear or branched, saturated or unsaturated hydrocarbon group, and at least one of R1 and R2 is the acyl group.
    Type: Grant
    Filed: November 16, 2016
    Date of Patent: May 19, 2020
    Assignee: SHOWA DENKO K.K.
    Inventor: Daisuke Yagyu
  • Patent number: 10493050
    Abstract: A pharmacological composition for the treatment of bacterial and protozoal infections in a patient. The preferred pharmacological composition comprises a pharmaceutical carrier and an active composition selected from the group consisting of: a) an amount of sodium oxalate and an amount of oxalic acid, b) an amount of sodium citrate and an amount of citric acid, or c) mixtures of a) and b). The amounts and weight ratios of a) the sodium oxalate and oxalic acid, and b) the sodium citrate and citric acid in the active composition are such as to produce a safe and effective pharmacological composition. Sodium salts of other carboxylic acids may be used. The invention also relates to the method of using the pharmacological composition for the safe and effective treatment of bacterial infections, protozoal infections and dermatological diseases.
    Type: Grant
    Filed: February 8, 2018
    Date of Patent: December 3, 2019
    Inventor: Naeem Uddin
  • Patent number: 10383893
    Abstract: Disclosed is a composition for reducing the levels or level of glucose, malondialdehyde-modified LDL, homocysteine, and/or C-reactive protein in the blood. Specifically disclosed is a composition for reducing the level of at least one substance selected from the group consisting of glucose, malondialdehyde-modified LDL, homocysteine, and C-reactive protein in the blood, which comprises the following components (a) and (b): (a) at least one component selected from the group consisting of vitamin B12, vitamin B6, and folic acid; and (b) at least one component selected from the group consisting of zinc, selenium, and an antioxidant vitamin.
    Type: Grant
    Filed: October 23, 2008
    Date of Patent: August 20, 2019
    Assignee: NUTRI CO., LTD.
    Inventor: Susumu Kawaguchi
  • Patent number: 10285961
    Abstract: In an embodiment of the present disclosure, there is provided a composition for dissolving calcium oxalate crystals thereby inhibiting/preventing further growth of crystals. In some embodiments, such a composition comprises at least one stereoisomer of hydroxycitrate, a derivative of the organic acid citrate. Such a method comprises administering to the subject an effective amount of the aforementioned composition. In another embodiment, the present disclosure pertains to a method of treating kidney stone disorder. Such a method comprises administering to a subject in need thereof a therapeutically effective amount of the aforementioned composition. In yet another embodiment, the present disclosure relates to a method of treating calcium oxalate stone disease. In an embodiment, the method comprises administering to a subject in need thereof a therapeutically effective amount of the aforementioned composition.
    Type: Grant
    Filed: April 27, 2015
    Date of Patent: May 14, 2019
    Assignee: University of Houston System
    Inventors: Jeffrey D. Rimer, Jihae Chung, John Asplin
  • Patent number: 10155715
    Abstract: A fraction separated from crude crocetin by preparative HPLC, and identified using LC/MS and NMR as crocetinic acid, markedly regressed the proliferation and increased apoptosis in pancreatic cancer cells. Purified crocetinic acid showed more potency than 15 commercial or crude crocetin using proliferation and apoptosis as markers. Purified crocetinic acid also showed significant anti-tumorigenic activity against pancreatic cancer cells in a mouse model of pancreatic cancer. Given crocetinic acid's low toxicity, crocetinic acid could be used as a chemotherapeutic or chemopreventative agent for pancreatic cancer.
    Type: Grant
    Filed: October 7, 2011
    Date of Patent: December 18, 2018
    Assignees: The United States of America as represented by the Department of Veterans Affairs, University of Kansas, University of Missouri
    Inventors: Animesh Dhar, William G. Gutheil
  • Patent number: 10052318
    Abstract: Methods of treating mental disorders, including anxiety disorders such as obsessive-compulsive disorder, are provided. The methods comprise administering an effective amount of a glutamate modulator to an individual in need thereof. Also provided are methods of enhancing the activity of a serotonin reuptake inhibitor (SRI) comprising co-administering a glutamate modulator and a serotonin reuptake inhibitor. Pharmaceutical composition comprising a serotonin reuptake inhibitor and a glutamate modulator are also provided.
    Type: Grant
    Filed: May 15, 2014
    Date of Patent: August 21, 2018
    Assignee: YALE UNIVERSITY
    Inventors: Vladimir Coric, John H. Krystal, Gerard Sanacora
  • Patent number: 10016356
    Abstract: The present invention relates to a novel sebum secretion inhibitor and use thereof for the production of cosmetic and pharmaceutical, notably dermatological, compositions, intended for preventing and/or reducing the secretion of sebum and notably of squalene.
    Type: Grant
    Filed: November 23, 2009
    Date of Patent: July 10, 2018
    Assignee: BASF Beauty Care Solutions France S.A.S.
    Inventors: Nabil Abdul-Malak, Corinne Reymermier
  • Patent number: 9988407
    Abstract: Methods and compounds are disclosed for treating a disease or condition by inhibiting PSMA (Prostate Specific Membrane Antigen) using prodrugs of 2-PMPA.
    Type: Grant
    Filed: August 6, 2015
    Date of Patent: June 5, 2018
    Assignees: THE JOHNS HOPKINS UNIVERSITY, INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY AS CR V.V.I.
    Inventors: Barbara Slusher, Rana Rais, Marcela Krecmerova, Tomas Tichy, Pavel Majer, Andrej Jancarik
  • Patent number: 9961922
    Abstract: Improved animal feeds and/or waters are provided, which include amendments comprising one or more copolymer salts serving to reduce volatilized ammonia derived from the excrement of animals. The copolymers are preferably water soluble and have substantially equimolar amounts of maleic and itaconic moieties.
    Type: Grant
    Filed: October 9, 2013
    Date of Patent: May 8, 2018
    Assignee: Verdesian Life Sciences, LLC
    Inventor: John Larry Sanders
  • Patent number: 9889105
    Abstract: An in vivo method of inhibiting tumor growth, specifically pancreatic cancer, includes administering to a subject in need thereof an effective amount of a compound, composition, and/or a pharmaceutical formulation including crocetinic acid.
    Type: Grant
    Filed: April 7, 2014
    Date of Patent: February 13, 2018
    Assignees: U.S. Department of Veterans Affairs, Univ. of Kansas, The Curators of the Univ. of Missouri
    Inventors: Animesh Dhar, William G. Gutheil
  • Patent number: 9849104
    Abstract: Methods and formulations to reduce elevated levels of lipids and apolipoprotein B in subjects having type IIb hyperlipidemia. Methods for preventing, delaying or regressing complications of lipid disorders, including; type IIb hyperlipidemia, NAFLD, and NASH. Methods for preventing or delaying primary and secondary cardiovascular events. Kits useful for such methods. Methods for reducing hepatic fibrosis. Methods for reducing plasma fibrinogen levels.
    Type: Grant
    Filed: January 26, 2017
    Date of Patent: December 26, 2017
    Assignee: Gemphire Therapeutics Inc.
    Inventors: Charles L. Bisgaier, Daniela Carmen Oniciu
  • Patent number: 9820968
    Abstract: The present invention provides the compound Ormeloxifene [3, 4-trans-2,2-dimethyl-3-phenyl-4-p-(beta-pyrrolidinoethoxy) phenyl-7-methoxy chroman] as useful in inducing differentiation in wide range of myeloid leukemias including acute promyelocytic leukemia, acute myeloid leukemia and chronic myeloid leukemia where block in differentiation is common feature. Ormeloxifene induced differentiation that is marked by increase in differentiation marker proteins like C/EBP? and surface proteins such as cd11b and granulocyte colony stimulating factor receptor (GCSFr). Differentiated cells having neutrophil like morphology were observed when treated with 1.0 uM to 7.5 uM ORM which clearly indicates that ORM can induce differentiation in myeloid leukemia cells. At higher doses (5 uM to 7.5 uM) there is early onset of myeloid differentiation (24 to 48 h) with reduced no. of cells which is likely due to apoptotic effects of ORM at higher does.
    Type: Grant
    Filed: February 28, 2014
    Date of Patent: November 21, 2017
    Assignee: COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH
    Inventors: Pooja Pal, Savita Lochab, Jitendra Kumar Kanuajiya, Sabyasachi Sanyal, Arun Kumar Trivedi
  • Patent number: 9757407
    Abstract: Alterations of certain metabolite concentrations and fluxes that occur in response to viral infection are described. Host cell enzymes in the involved metabolic pathways are selected as targets for intervention; i.e., to restore metabolic flux to disadvantage viral replication, or to further derange metabolic flux resulting in “suicide” of viral-infected cells (but not uninfected cells) in order to limit viral propagation. While any of the enzymes in the relevant metabolic pathway can be selected, pivotal enzymes at key control points in these metabolic pathways are preferred as candidate antiviral drug targets. Inhibitors of these enzymes are used to reverse, or redirect, the effects of the viral infection. Drug candidates are tested for antiviral activity using screening assays in vitro and host cells, as well as in animal models. Animal models are then used to test efficacy of candidate compounds in preventing and treating viral infections. The antiviral activity of enzyme inhibitors is demonstrated.
    Type: Grant
    Filed: December 21, 2015
    Date of Patent: September 12, 2017
    Assignee: The Trustees of Princeton University
    Inventors: Josh Munger, Bryson Bennett, Thomas Shenk, Joshua Rabinowitz
  • Patent number: 9468597
    Abstract: An aqueous topical serum having stabilized bioactive L-ascorbic acid has a pH of from 3.4 to 3.8 and comprises from 10% to 18% by weight of L(+)-ascorbic acid, 0.2% by weight retinyl propionate, and from 0.005% to 0.5% by weight of a mixture selected from the group consisting of glabridin, silibinin and thyme.
    Type: Grant
    Filed: March 17, 2014
    Date of Patent: October 18, 2016
    Assignee: Dr. Perry Skindustries, LLC
    Inventor: Arthur William Perry
  • Patent number: 9346914
    Abstract: The present invention is directed toward a series of polyesters synthesized utilizing propane diol with tunable ascetics and performance in cosmetic formulation. These novel propane diol polyesters are designed to have great esthetics in cosmetic formulation. The physical properties and aesthetics of the current invention can be tuned rapidly by controlling the fatty groups, as well as the molecular weight of the polymer. The resulting propane diol polyesters have outstanding aesthetics and physical properties.
    Type: Grant
    Filed: October 14, 2014
    Date of Patent: May 24, 2016
    Assignee: SURFATECH CORPORATION
    Inventor: Thomas George O'Lenick
  • Patent number: 9192188
    Abstract: A dietary supplement and method of supplementation comprises a vegetable component consisting essentially of juices extracted from two parts by weight fresh, unpeeled carrots; one part by weight fresh, unpeeled beet root; one part by weight of fresh, unpeeled cucumber; and a selected quantity of aloe vera juice. A cleansing component includes at least one of the following: about 2 fluid ounces (59.1 ml) of lemon juice; about 1.5-2 fluid ounces (44.3 to 59.1 ml) of lime juice; about 1 fluid ounce (29.6 ml) of aloe vera juice; and about 4-6 fluid ounces (118.3 to 177.4 ml) of cranberry juice. The vegetable component is ingested orally twice daily and the cleansing component is ingested orally once daily.
    Type: Grant
    Filed: March 12, 2013
    Date of Patent: November 24, 2015
    Inventor: Delphine Agatha O'Connor-Smith
  • Patent number: 9173838
    Abstract: The present invention relates to a method for the preparation of reverse micelles based on sterols, acylglycerols and metal salt and to reverse micelles obtained thereby. They are advantageously useful in the pharmaceutical and dietetic fields.
    Type: Grant
    Filed: November 2, 2005
    Date of Patent: November 3, 2015
    Assignee: MEDESIS PHARMA SA
    Inventor: Jean-Claude Maurel
  • Publication number: 20150148287
    Abstract: A liquid excipient is added to a lock solution formulation containing a lower alcohol and an anti-coagulant, antibiotic, and/or anti-microbial, such as the ethanol and tri-sodium citrate lock solution formulation, to prevent citrate from crystallizing in catheters made from silicone. The locking solution could include a liquid excipient, such as glycerol, polysorbate-20, or polyethylene glycol (PEG)-400, along with a lower alcohol, such as ethanol, and an anti-coagulant, such as tri-sodium citrate, antibiotic, and/or anti-microbial.
    Type: Application
    Filed: November 25, 2014
    Publication date: May 28, 2015
    Applicant: EXCELSIOR MEDICAL CORPORATION
    Inventors: Lecon Woo, William Anderson
  • Patent number: 9034390
    Abstract: The present invention generally relates to anti-microbial formulations and methods of their use and production. The formulations of the present invention are effective as broad spectrum anti-bacterial agents with efficacy against both Gram-negative and Gram-positive bacteria, as anti-viral agents with efficacy against both enveloped and non-enveloped viruses, and as anti-fungal agents with efficacy against both vegetative and spore forms of microorganisms and against biofilms. The present invention includes anti-microbial compositions that have at least one surfactant, at least one acid, at least one peroxide (preferably hydrogen peroxide), peracetic acid, and water. The anti-microbial Formulations of the present invention may additionally contain an organic salt. The organic salt may be a salt of the same acid that is used in the Formulation or a salt of a different acid. Methods for production and use of the inventive compositions are disclosed.
    Type: Grant
    Filed: May 10, 2007
    Date of Patent: May 19, 2015
    Assignee: BIONEUTRAL LABORATORIES CORPORATION
    Inventor: Andrew Kielbania, Jr.
  • Patent number: 9034319
    Abstract: A method of treating a cancer of the central nervous system in a subject in need thereof is provided. The method comprising administering to the subject a therapeutically effective amount of an agent which reduces blood glutamate levels and enhances brain to blood glutamate efflux to thereby treat the cancer of the central nervous system in the subject.
    Type: Grant
    Filed: May 26, 2008
    Date of Patent: May 19, 2015
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Vivian I. Teichberg, Angela Ruban-Matuzani
  • Publication number: 20150125426
    Abstract: A composition comprising medium chain dicarboxylic acids and/or derivatives of medium chain dicarboxylic acids can be used to treat or prevent metabolic disorders. The composition can particularly well be used to treat or prevent hyperglycemia, for example diabetes.
    Type: Application
    Filed: January 9, 2015
    Publication date: May 7, 2015
    Inventors: Geltrude Mingrone, Catherine Mace
  • Patent number: 9023892
    Abstract: A compound for use as an antimicrobial having a formula (A).
    Type: Grant
    Filed: December 21, 2010
    Date of Patent: May 5, 2015
    Inventors: Allan James McKinley, Thomas V. Riley, Nigel Lengkeek, Scott Stewart, Ramiz Boulos
  • Publication number: 20150119321
    Abstract: A unique combination of weight loss modalities that produce 20-40 pounds of weigh loss in a six week treatment period. Treatment includes a meal plan chosen to provide adequate protein and nutrition during dieting and to assist metabolism of toxins created from the release of stored fat, high amounts of fiber to assist in collecting toxins and fat in the elimination system and to encourage peristaltic action in the bowel, a bowel toner to further increase peristaltic action in the bowel, stimulating liver functions of fat and toxins. The weight loss portion of the treatment is limited to six week segments, and added to the plurality of modalities comprising the invention, to further support the body during weight loss. By supporting the body during weight loss, his invention(s) avoids the “plateau” routinely experienced by existing weight loss systems, when the metabolism slows to avoid further damage from ultra-low calories, medications, bariatric surgeries, and other stressful programs.
    Type: Application
    Filed: April 5, 2013
    Publication date: April 30, 2015
    Inventor: Linda Duerler FINCH
  • Publication number: 20150110773
    Abstract: Methods and kits for GPP-targeting, e.g., for the treatment of oncogenic Kras-associated cancers, and methods for determining the efficacy of those methods are provided.
    Type: Application
    Filed: May 23, 2013
    Publication date: April 23, 2015
    Inventors: Alec C. Kimmelman, Jaekyoung Son, Lewis Cantley, Costas A. Lyssiotis
  • Patent number: 9012689
    Abstract: The present invention relates to a compound of formula A, wherein R is alkyl. Compound A may be used as an intermediate in the preparation of O-desmethyl venlafaxine or a salt thereof, and the present invention provides such a preparation, as well as a process for preparing the compound of formula A.
    Type: Grant
    Filed: July 14, 2010
    Date of Patent: April 21, 2015
    Assignee: Cipla Limited
    Inventors: Rajendra Narayanrao Kankan, Dharmaraj Ramachandra Rao, Manohar Raghunath Surve
  • Publication number: 20150104531
    Abstract: Methods of inhibiting a phosphodiesterase (PDE) 7 enzyme such as PDE7A1 and methods for treating diseases associated with PDE7 using one or more trans-aconitic acid compounds, which can be isolated from plants.
    Type: Application
    Filed: October 13, 2014
    Publication date: April 16, 2015
    Inventors: Shui-Tein CHEN, I-Shu LEE, Yu-Chun CHEN
  • Publication number: 20150105460
    Abstract: Provided in the present invention are various labdane diterpenoid compounds and derivatives thereof for use in preparation of a pharmaceutical composition for preventing or treating neurodegenerative diseases. Also provided in the present invention is a semen biotae extract comprising one or more labdane diterpenoid compounds and derivatives thereof for use in preparation of a pharmaceutical composition for preventing or treating neurodegenerative diseases.
    Type: Application
    Filed: June 4, 2012
    Publication date: April 16, 2015
    Inventors: Weiwei Su, Yonggang Wang, Fengyin Liang, Ning Wang, Zhong Pei, Haibin Liu
  • Publication number: 20150104429
    Abstract: Synthetic triterpenoids and methods of using the same to induce gene expression and differentiation of stem or progenitor cells are provided. Furthermore, the present invention provides methods for producing a cell, such as a stem or progenitor cell, with induced gene expression by contacting a stem or progenitor cell with an effective amount of a synthetic triterpenoid to induce the expression of one or more of SOX9 (Sex determining region Y-box 9), COL2A1 (Type II Collagen (alpha1)), TGF-?I, TGF-p2, TGF-33, BMP2, BMP4, BMPRII (Bone Morphogenic Protein Receptor II), SMAD (Small Mothers Against Decapentaplegic) 3, SMAD4, SMAD6, SMAD7, TIMP (Tissue Inhibitor of Metalloproteinase)-1 or TIMP-2 in the stem or progenitor cell, wherein the stem or progenitor cell is not a mesenchymal stem cell, periosteium cell or osteoprogenitor cell. In one embodiment, the stem or progenitor cell is multipotent.
    Type: Application
    Filed: May 7, 2013
    Publication date: April 16, 2015
    Inventors: Gordon W. Gribble, Liangfeng Fu, Michael B. Sporn, Karen T. Liby
  • Patent number: 8999400
    Abstract: An aqueous disinfecting solution having a pH of from about 0.5 to about 6 consists essentially of hydrogen peroxide in a concentration of from about 0.05 to about 8 w/w % of the total solution, at least one anionic surfactant in a concentration of from about 0.02 to about 8 w/w % of the total solution, and at least one additional ingredient chosen from benzyl alcohol, an alcohol comprising one to six carbon atoms, and mixtures thereof, in a concentration of from about 0.1 to about 10 w/w % of the total solution.
    Type: Grant
    Filed: March 2, 2012
    Date of Patent: April 7, 2015
    Assignee: Virox Technologies Inc.
    Inventors: Jose A. Ramirez, Navid Omidbakhsh
  • Publication number: 20150093478
    Abstract: An absorbent pad that contains activated carbon to reduce confinement odor in a vacuum-packaged food product is provided. An embodiment of absorbent pad contains activated carbon and an antimicrobial agent that further reduces confinement odor by two mechanisms of action: reducing bacterial counts in the liquid purge that cause breakdown of carbohydrates and proteins in food products; and trapping of confinement odor-causing breakdown products by the activated carbon. The absorbent body in the absorbent pad actively draws in liquid purge and dissolved volatile breakdown products in the vacuum package that produce confinement odor, which produces greater and more rapid contact of odor-causing compounds with the activated carbon.
    Type: Application
    Filed: September 26, 2014
    Publication date: April 2, 2015
    Inventors: Sayandro Versteylen, Brett N. Stoll, Martin H. Michaels
  • Patent number: 8992954
    Abstract: The present invention relates to compositions comprising a derivative of 5-aminolevulinic acid (5-ALA), e.g. an ester of 5-ALA or a skin compatible salt thereof. Further, the invention relates to use of such compositions in methods of cosmetic treatment, particularly in methods of improving or otherwise enhancing the appearance of the skin.
    Type: Grant
    Filed: March 1, 2011
    Date of Patent: March 31, 2015
    Assignee: Photocure ASA
    Inventors: Oddveig Sellæg Helland, Stig Ove Johnsen, Enrique Alabata, Anja J. Jentoft, Aslak Godal
  • Publication number: 20150079144
    Abstract: A lubricious antiseptic coating material containing various solvents to achieve mutual miscibility and provide a generally homogenous product. A coating material is provided having an antipathogenic agent and a solvent for dissolving the same. The coating further includes a lubricious agent and a solvent for dissolving the same. Thus, the coating material contains antiseptic and lubricious properties suitable for application to a desired surface to kill or inhibit the growth of pathogens known to cause catheter related bloodstream infections.
    Type: Application
    Filed: November 19, 2014
    Publication date: March 19, 2015
    Inventors: Minh Quang Hoang, Mohammad A. Khan
  • Patent number: 8980344
    Abstract: The present invention provides a skin care product comprising at least two enhancers and at least one skin care ingredient, wherein the at least two enhancers are selected from cyclodextrin, pentasodium pentetate, phytic acid, potassium citrate, sodium citrate, potassium gluconate and sodium gluconate.
    Type: Grant
    Filed: October 1, 2008
    Date of Patent: March 17, 2015
    Inventor: Dennis F. Gross
  • Publication number: 20150064285
    Abstract: The present invention provides compositions that contain magnesium and threonate, or a threonate precursor molecule, formulated for extended or modified release to provide physiological concentrations over a desired time period. The extended release or modified release form is particularly useful in providing Mg to a subject while avoiding adverse side effects such as diarrhea.
    Type: Application
    Filed: March 21, 2014
    Publication date: March 5, 2015
    Applicant: Magceutics, Inc.
    Inventors: Guosong LIU, Fei Mao
  • Patent number: 8962689
    Abstract: The present invention relates in general to medium chain dicarboxylic acids, their derivatives and their uses. In particular, the present invention relates to a composition comprising medium chain dicarboxylic acids and to the use of medium chain dicarboxylic acids and their derivatives for the preparation of products to treat or prevent metabolic disorders. The composition of the present invention can particularly well be used to treat or prevent hyperglycemia, for example diabetes.
    Type: Grant
    Filed: March 9, 2009
    Date of Patent: February 24, 2015
    Assignee: Nestec S.A.
    Inventors: Geltrude Mingrone, Catherine Mace
  • Patent number: 8957113
    Abstract: Disclosed are immediate release oral tranexamic acid formulations and methods of treatment therewith.
    Type: Grant
    Filed: January 28, 2011
    Date of Patent: February 17, 2015
    Assignee: Ferring B.V.
    Inventors: Keith A. Moore, Ralph A. Heasley, Jeffrey S. Greiwe, John W. Facemire, Jason D. Modest